Status:
COMPLETED
Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
propatient foundation Basel
Conditions:
Staphylococcus Aureus Infection
Eligibility:
All Genders
18+ years
Brief Summary
Given the paucity of pharmacological data on cefazolin treatment of Methicillin-susceptible S. aureus (MSSA) complicated S. aureus infection (CSAI), the primary purpose of this study is to investigate...
Eligibility Criteria
Inclusion
- CSAI caused by MSSA. CSAI is defined as MSSA BSI with a positive follow-up blood culture result for MSSA or the presence of a site of infection remote from the primary focus caused by hematogenous seeding (e.g. endocarditis, vertebral osteomyelitis) or extension of the infection beyond the primary focus (e.g. septic thrombophlebitis or abscess); or deep-seated infections caused by MSSA (e.g. osteoarticular infections, deepseated abscesses).
- Current or intended treatment with cefazolin
Exclusion
- Previous enrolment into the current study within 30 days
- Hemodialysis (patients on hemofiltration are eligible)
- Patients who are very likely to stop treatment with cefazolin in the next 48 hours as per treating physician (because of treatment failure, switch to oral medication, palliative care, allergy etc.) or who are very likely to be discharged in the next 48 hours as per treating physician.
- Outpatients
- Women who are pregnant (special pharmacokinetic)
- Polymicrobial infection except concomitant isolation of a likely contaminant (e.g. Staphylococcus epidermidis or Propionibacterium acnes) or an anaerobic pathogen. If an additional pathogen is identified after inclusion of the patient into the study, the patient will remain in the study.
- Not-complicated S. aureus infections: non-bacteremic skin- and soft tissue or small Joint infections without deep-seated abscesses (as these patients will be quickly switched to oral antibiotics)
- CSAI caused by methicillin-resistant S. aureus (MRSA)
- Additional exclusion criteria for the sub-study investigating cefazolin concentrations in sweat:
- Allergic to pilocarpine
- Continuous oxygen therapy without the possibility to interrupt oxygen administration for 10min
- Pacemaker
Key Trial Info
Start Date :
January 14 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 28 2022
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04503252
Start Date
January 14 2020
End Date
March 28 2022
Last Update
March 29 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Basel, Division of Internal Medicine
Basel, Switzerland, 4031